Takeda Pharmaceutical Company, a research-based global company, has acquired a biologics manufacturing facility located in Brooklyn Park, Minnesota (US), from Baxalta US.

 

The firm intends to use the facility primarily for the manufacture of Entyvio (vedolizumab) and other biologic products, allowing the company to maximise global efficiencies and further enhance the product’s supply chain flexibility, said a statement.

 

Thomas Wozniewski, global manufacturing and supply officer, Takeda, said: “Takeda’s focus is providing patients access to quality therapies. Acquiring the state of the art Brooklyn Park facility and gaining access to a highly experienced and dedicated team is a very important strategic benefit for Takeda that reinforces and expands upon our global operations for Entyvio and future biologic products.”

 

The acquisition will also provide long-term strategic benefits for Takeda through enhanced capacities for the manufacture of additional commercial products and investigational drugs under clinical development, said the statement.

 

The plant will allow Takeda to establish and develop direct commercial bio-manufacturing expertise. 

 

Terms of the transaction were not disclosed, it added. - TradeArabia News Service